NEJM study found Zetia uptake rose quicker in US vs. Canada

Share this article:
A New England Journal of Medicine study found Zetia uptake rose much more quickly after introduction in the US than in Canada, and suggested DTC was the main culprit. “Despite the absence of data regarding clinical outcomes, ezetimibe was heavily promoted,” the study's authors wrote, citing Nielsen numbers showing that more than $200 million was spent advertising Vytorin to US consumers in 2007, while consumer ads are prohibited in Canada.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.